
Accepted Manuscript

Anti-Tumour Treatment

Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma

Michael R. Migden, Anne Lynn S. Chang, Luc Dirix, Alexander J. Stratigos, John T. Lear

PII:	S0305-7372(17)30211-6
DOI:	https://doi.org/10.1016/j.ctrv.2017.12.009
Reference:	YCTRV 1716
To appear in:	Cancer Treatment Reviews Cancer Treatment Re- views
Received Date:	28 April 2017
Revised Date:	11 December 2017
Accepted Date:	12 December 2017



Please cite this article as: Migden, M.R., Chang, A.L.S., Dirix, L., Stratigos, A.J., Lear, J.T., Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: https://doi.org/10.1016/j.ctrv.2017.12.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma

Authors: Michael R. Migden,^{a,*} Anne Lynn S. Chang,^b Luc Dirix,^c Alexander J. Stratigos,^d John T. Lear^e

Affiliations: ^aDepartments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ^bStanford University School of Medicine, Redwood City, CA, USA; ^cSint-Augustinus Ziekenhuis, Antwerp, Belgium; ^dDepartment of Dermatology – Venereology, Andreas Syggros Hospital, National and Kapodestrian University of Athens, Athens, Greece; ^eManchester Academic Health Science Centre, University of Manchester, Manchester, UK

* Corresponding author at: University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1452, Houston, TX 77030, USA.

Email address: mrmigden@mdanderson.org

Journal: Cancer Treatment Reviews Abstract: max 250 words (currently, 248) Word count: max 5000 words (currently, 4656) Figures/tables: max 6 (currently, 1 figure; 4 tables) References: max 100 (currently, 83)

Funding: Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. Download English Version:

https://daneshyari.com/en/article/8785894

Download Persian Version:

https://daneshyari.com/article/8785894

Daneshyari.com